文献速递浆细胞疾病

新诊断多发性骨髓瘤早期免疫重建的外周血生物标志物

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma.
PubMed 文献 · Am J Hematol · 2018-12-13

研究纳入771例新诊断多发性骨髓瘤患者,在治疗开始时及之后1个月检测绝对淋巴细胞计数和绝对单核细胞计数。基线无免疫失调者总生存更优(HR 0.77,95% CI 0.61-0.97,P=0.025);1个月时无免疫失调者总生存更优(HR 0.63,95% CI 0.50-0.80,P<0.001);早期免疫重建者总生存更优(HR 0.62,95% CI 0.43-0.92,P=0.016)。

要点

  • 基线无免疫失调者较有免疫失调者总生存更优(HR 0.77,95% CI 0.61-0.97,P=0.025,n=771)。
  • 1个月时无免疫失调者较持续或新发免疫失调者总生存更优(HR 0.63,95% CI 0.50-0.80,P<0.001,n=771)。
  • 早期免疫重建者较持续或新发免疫失调者总生存更优(HR 0.62,95% CI 0.43-0.92,P=0.016,n=771)。

核心结论

  • 新诊断多发性骨髓瘤中免疫失调的存在或出现是独立风险因素。
  • 早期免疫重建的有利影响提示免疫失调可能是可改变的风险因素,或可用于治疗获益。

研究设计与样本

  • 研究纳入771例新诊断多发性骨髓瘤患者,在治疗开始时及之后1个月检测绝对淋巴细胞计数和绝对单核细胞计数。

主要发现

  • 234例患者(31%)在基线有免疫失调证据(生物标志物异常)。
  • 这些患者中87例(37%)在1个月时生物标志物恢复正常(早期免疫重建)。
  • 基线无免疫失调较有免疫失调者总生存更优(HR 0.77,95% CI 0.61-0.97,P=0.025,n=771)。
  • 1个月时无免疫失调较持续或新发免疫失调者总生存更优(HR 0.63,95% CI 0.50-0.80,P<0.001,n=771)。
  • 早期免疫重建较持续或新发免疫失调者总生存更优(HR 0.62,95% CI 0.43-0.92,P=0.016,n=771)。

关键数值与推荐

  • 细胞遗传学高危疾病与早期免疫重建负相关,免疫调节剂治疗与早期免疫重建正相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral blood biomarkers of tumor microenvironment and immune surveillance are independent prognostic factors in multiple myeloma. The timing and prognostic impact of immune reconstitution has been studied after autologous hematopoietic stem cell transplantation, less is known about its significance in newly diagnosed multiple myeloma. We studied absolute lymphocyte (ALC) and absolute monocyte (AMC) counts at the time of treatment initiation and 1 month thereafter in 771 newly diagnosed patients. Two hundred and thirty-four patients (31%) had evidence of immune dysregulation at baseline (abnormal biomarkers). Eighty-seven of these patients (37%) recovered normal biomarkers at 1 month (early immune reconstitution). The absence of immune dysregulation at baseline (compared to the presence thereof) was associated with better overall survival (HR 0.77, 95% CI 0.61-0.97, P = 0.025, n = 771). The absence of immune dysregulation at 1 month (compared to the persistence or development thereof) was associated with better overall survival (HR 0.63, 95% CI 0.50-0.80, P < 0.001, n = 771). Early immune reconstitution (compared to the persistence or development of immune dysregulation) was associated with better overall survival (HR 0.62, 95% CI 0.43-0.92, P = 0.016, n = 771). Cytogenetic high-risk disease was negatively, and treatment with immunomodulators positively, associated with early immune reconstitution. The presence or development of immune dysregulation in newly diagnosed multiple myeloma is an independent risk factor. The favorable impact of early immune reconstitution suggests immune dysregulation to be a potentially modifiable risk factor that may be exploited for therapeutic benefit.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Binder M, Rajkumar SV, Lacy MQ, et al. Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. Am J Hematol. 2018. PMID: 30516847. doi:10.1002/ajh.25365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。